| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
3205 Stock Overview
Sagittarius Life Science Corp researches and develops plant drugs in Taiwan.
Sagittarius Life Science Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$46.40 |
| 52 Week High | NT$79.20 |
| 52 Week Low | NT$20.65 |
| Beta | 0.30 |
| 1 Month Change | -39.58% |
| 3 Month Change | 26.43% |
| 1 Year Change | 81.25% |
| 3 Year Change | -11.28% |
| 5 Year Change | -39.03% |
| Change since IPO | -61.29% |
Recent News & Updates
Shareholder Returns
| 3205 | TW Personal Products | TW Market | |
|---|---|---|---|
| 7D | -12.3% | -5.8% | -5.5% |
| 1Y | 81.3% | -6.2% | -19.3% |
Return vs Industry: 3205 exceeded the TW Personal Products industry which returned -6.2% over the past year.
Return vs Market: 3205 exceeded the TW Market which returned -19.3% over the past year.
Price Volatility
| 3205 volatility | |
|---|---|
| 3205 Average Weekly Movement | 11.9% |
| Personal Products Industry Average Movement | 5.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 3205 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: 3205's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | n/a | https://www.naturalbiokey.com |
Sagittarius Life Science Corp researches and develops plant drugs in Taiwan. The company engages in the development of Chinese herbal medicine technology platform for the treatment of various diseases. It also offers nutritional supplements, health foods, and health related products.
Sagittarius Life Science Fundamentals Summary
| 3205 fundamental statistics | |
|---|---|
| Market Cap | NT$1.51b |
| Earnings (TTM) | -NT$91.10m |
| Revenue (TTM) | NT$555.27m |
2.7x
P/S Ratio-16.6x
P/E RatioIs 3205 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3205 income statement (TTM) | |
|---|---|
| Revenue | NT$555.27m |
| Cost of Revenue | NT$469.13m |
| Gross Profit | NT$86.14m |
| Other Expenses | NT$177.24m |
| Earnings | -NT$91.10m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.80 |
| Gross Margin | 15.51% |
| Net Profit Margin | -16.41% |
| Debt/Equity Ratio | 0% |
How did 3205 perform over the long term?
See historical performance and comparisonValuation
Is 3205 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3205?
Other financial metrics that can be useful for relative valuation.
| What is 3205's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | NT$1.51b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.5x |
| Enterprise Value/EBITDA | -15x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 3205's PS Ratio compare to its peers?
| 3205 PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.1x | ||
6703 Shiny Brands Group | 1.4x | n/a | NT$2.0b |
1731 Maywufa | 1.8x | n/a | NT$2.4b |
4732 NatureWise Biotech & Medicals | 5.2x | n/a | NT$1.5b |
1796 GeneFerm Biotechnology | 3.9x | n/a | NT$2.3b |
3205 Sagittarius Life Science | 2.7x | n/a | NT$1.5b |
Price-To-Sales vs Peers: 3205 is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does 3205's PE Ratio compare vs other companies in the TW Personal Products Industry?
Price-To-Sales vs Industry: 3205 is expensive based on its Price-To-Sales Ratio (2.7x) compared to the TW Personal Products industry average (2.7x)
Price to Sales Ratio vs Fair Ratio
What is 3205's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 3205's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 3205 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 3205's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 3205's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Sagittarius Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.8%
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sagittarius Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Sagittarius Life Science's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
Past Performance
How has Sagittarius Life Science performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-2.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3205 is currently unprofitable.
Growing Profit Margin: 3205 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3205 is unprofitable, and losses have increased over the past 5 years at a rate of 2% per year.
Accelerating Growth: Unable to compare 3205's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3205 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-11.6%).
Return on Equity
High ROE: 3205 has a negative Return on Equity (-18.95%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Sagittarius Life Science's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 3205's short term assets (NT$349.6M) exceed its short term liabilities (NT$97.0M).
Long Term Liabilities: 3205's short term assets (NT$349.6M) exceed its long term liabilities (NT$32.8M).
Debt to Equity History and Analysis
Debt Level: 3205 is debt free.
Reducing Debt: 3205 had no debt 5 years ago.
Debt Coverage: 3205 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 3205 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is Sagittarius Life Science current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
| Sagittarius Life Science Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (Sagittarius Life Science) | 0% |
| Market Bottom 25% (TW) | 2.6% |
| Market Top 25% (TW) | 7.0% |
| Industry Average (Personal Products) | 3.8% |
| Analyst forecast in 3 Years (Sagittarius Life Science) | n/a |
Notable Dividend: Unable to evaluate 3205's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 3205's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3205's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3205's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 3205 is not paying a notable dividend for the TW market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 3205 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Sagittarius Life Science has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
| Owner Type | Number of Shares | Ownership Percentage |
|---|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Company Information
Sagittarius Life Science Corp's employee growth, exchange listings and data sources
Key Information
- Name: Sagittarius Life Science Corp
- Ticker: 3205
- Exchange: TPEX
- Founded: 1998
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: NT$1.510b
- Shares outstanding: 32.55m
- Website: https://www.naturalbiokey.com
Number of Employees
Location
- Sagittarius Life Science Corp
- No.3, Yuanqu Street
- 10F-6
- Taipei
- 115
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 3205 | TPEX (Taipei Exchange) | Yes | Common Stock | TW | TWD | May 2004 |
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/09/30 00:00 |
| End of Day Share Price | 2022/09/29 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.